Sanofi’s LixiLan diabetes drug shows positive results in a second late-stage
Pharmaceutical company Sanofi announced on Monday that a second late-stage Phase III clinical trial of its new diabetes medication LixiLan had met its primary target.
Posted On Sep 15 2015